There is a correlation between CCR7 expression, receptor for both CCL21 and CCL19, and clinical lymphadenopathy, and blocking CCR7 suppresses TEM of CLL cells (260). Here, CCR7 is linked to B-cell chronic lymphocytic leukemia.